Moderna Stock Flashes Warning After 177% Surge

Moderna and Merck developed a personalized cancer vaccine using AI to identify tumor-specific markers. The vaccine, administered with Keytruda, showed early promise in preventing melanoma recurrence. Full trial data will be presented later this year. Moderna's stock more than doubled, and Merck's shares also rose significantly following the announcement.

Merck (MRK) and Moderna (MRNA) reported positive phase 3 trial results for an mRNA-based skin cancer treatment, called autogenous intismeran, combined with Merck's Keytruda. The therapy showed a statistically significant improvement in relapse-free survival for advanced melanoma patients post-surgery. Moderna shares rose over 2.5x, adding $40B to its market cap, while Merck shares increased over 12%. Full data will be presented at a medical congress, and regulatory approval processes will follow

Moderna and Merck reported positive late-stage trial results for their personalized cancer vaccine, which, when combined with Merck's Keytruda, showed improved outcomes in melanoma patients compared to Keytruda alone. The trial included one patient from NYU Langone Hospital. Moderna's stock surged after the announcement, rising from $62.96 to $174.38, though it later gave back some gains. Merck's stock also increased. The companies plan to present the data at an upcoming medical meeting and shar

Moderna and Merck reported positive results from a late-stage trial of their personalized mRNA cancer vaccine, intismeran, showing reduced cancer recurrence in high-risk melanoma patients. The vaccine uses mRNA technology to target specific tumor neoantigens. Moderna's mRNA flu vaccine, mRNA-1010, was recently FDA-approved for adults 50+.

Elon Musk described curing diseases as increasingly similar to solving a software problem, citing advances in AI and mRNA technology. Moderna and Merck reported positive results from a late-stage trial of a personalized mRNA cancer vaccine for melanoma, reducing the risk of cancer returning. AI helps analyze genetic data to identify treatment targets, enabling personalized medicine. Moderna is exploring similar approaches for other cancers, though challenges remain in production and affordabilit

Moderna's stock fell Thursday, reducing its market cap by $18B after a record surge following positive cancer vaccine trial results. Co-founders and CEO saw significant net worth changes. Analysts view the trial as critical for Moderna's stock. The company's revenue is $145M with a net loss of $782M in the latest quarter, per the company.